



### **Abgenix Files Resale Registration Statement**

FREMONT, Calif., March 17 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody therapeutics, announced today it has filed a resale registration statement on Form S-3 with the U.S. Securities and Exchange Commission covering its 1.75 percent Convertible Senior Notes due December 2011 and the common stock issuable upon conversion of the notes. As previously announced, the notes were issued in a private placement in December 2004. The Company did not issue any new securities and will not receive any proceeds from the resale of securities under this registration statement.

#### About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through its own development efforts and the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at [www.abgenix.com](http://www.abgenix.com).

Statements made in this press release about Abgenix's technologies, product development activities, collaborative arrangements and process science and manufacturing capabilities, other than statements of historical fact, and about its projected financial results and the achievement of milestone or similar payments, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, product manufacturing, regulatory approval processes, competitive products and services, future capital requirements, the extent and breadth of Abgenix's patent portfolio and other factors set forth in Abgenix's public filings with the Securities and Exchange Commission, including the risks described in Abgenix's annual report on Form 10-K for the year ended December 31, 2004. Abgenix is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statement

SOURCE Abgenix, Inc.

03/17/2005

CONTACT: Ami Knoefler, Senior Director of Corporate Communications and Investor Relations, of Abgenix, Inc., +1-510-284-6350, or +1-510-284-6605/ Web site: <http://www.abgenix.com>